Table 3.
Ongoing clinical trials of novel agents in patients with different types of cancers with TP53.
| Drug | Targeting gene | Clinical trials | Number | First report time—last report time | Status |
|---|---|---|---|---|---|
| HDM201 | TP53 | To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53 | NCT02143635 | May 21, 2014–February 23, 2018 | Recruiting |
| SNX-5422 | TP53 | A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers | NCT02612285 | November 23, 2015–November 4, 2016 | Terminated |
| AZD-1775 | TP53 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation | NCT02688907 | February 23, 2016–February 7, 2018 | Recruiting |
| AMG-232 | TP53, MDM2 | MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma | NCT03107780 | April 11, 2017–March 5, 2018 | Recruiting |
| Anti-p53 protein | TP53 | Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | NCT00393029 | October 26, 2006–August 15, 2011 | Completed |
MDM2: mouse double minute 2 homolog.